|
|
Differential Expression and Clinical Significance of EGFR gene in Tissue and Plasma in Advanced NonSmall Cell Lung Cancer |
First Department of Thoracic Medicine, Hunan Cancer Hospital, 410013 |
|
|
Abstract 【Objective】To investigate the expression and clinical significance of epidermal growth factor receptor (EGFR) gene (DNA) in tissue and plasma of patients with advanced nonsmall cell lung cancer (NSCLC).【Methods】Sixtyfive cases of NSCLC in our hospital from March to June 2015 were selected, and the plasma and tissue samples were extracted, EGFR DNA gene mutation were detected and compared.【Results】EGFR gene mutations were detected in 23 cases out of 65 patients, and the mutation rate was 35.4%;12 cases were detected in circulating DNA, the mutation rate was 18.5%. The specificity of EGFR gene mutation detection of the plasma DNA was 93.8%; the sensitivity was 43.5%. The mutation rate of EGFR gene was 22.7% in 44 male patients in the tissue samples; the mutation rate of EGFR gene in 21 female patients was 61.9%, the difference was statistically significant (P<0.05). The mutation rate of EGFR gene was 17.1% (7/41) in 41 patients with smoking; EGFR mutation rate was 66.7% (16/24) in 24 patients without smoking, and there was a significant difference between the two groups (P<0.05). The mutation rate of EGFR was 46.3% in 41 cases of adenocarcinoma and the EGFR mutation rate of 24 cases of non adenocarcinoma patients was 16.7%, the difference was statistically significant (P<0.05).The distribution of EGFR gene mutations in plasma was consistent with the results of tumor tissue detection. There were statistically significant differences in different gender, smoking status and different pathological types (P<0.05). There was no significant difference in tumor stage (P>0.05).【Conclusion】 For patients with advanced NSCLC, detection of EGFR DNA gene mutation in plasma circulation has high specificity and low sensitivity, which can be used in the supplementary diagnosis.
|
Received: 04 May 2016
|
|
|
|
|
|
|